Saha, T. (2024). Inhaled dry powder to treat respiratory infections (PhD). University of Otago, Dunedin, New Zealand. Retrieved from http://hdl.handle.net/10523/16645
Awarded Doctoral Degree
Saha, T., Lyons, N., Yung, D. B. Y., Quiñones‑Mateu, M. E., Pletzer, D., & Das, S. C. (2024). Repurposing ebselen as an inhalable dry powder to treat respiratory tract infections. European Journal of Pharmaceutics & Biopharmaceutics, 195, 114170. doi: 10.1016/j.ejpb.2023.12.010
Journal - Research Article
Saha, T., Lyons, N., Yung, D., Pletzer, D., Quiñones Mateu, M. E., & Das, S. (2023). Inhalable ebselen dry powder for respiratory tract infections. Pharmacy Education, 23(6), (pp. 147). doi: 10.46542/pe.2023.236.129157
Conference Contribution - Published proceedings: Abstract
Saha, T., Sinha, S., Harfoot, R., Quiñones‑Mateu, M. E., & Das, S. C. (2023). Development of inhalable dry powders combining replication and protease inhibitors of SARS-CoV-2. Proceedings of the 34th Drug Delivery to the Lungs (DDL) Conference. 34, (pp. 389-392). Retrieved from https://ddl-conference.com
Conference Contribution - Published proceedings: Full paper
Saha, T., Sinha, S., Harfoot, R., Quiñones‑Mateu, M. E., & Das, S. C. (2023). Inhalable dry powder containing remdesivir and disulfiram: Preparation and in vitro characterization. International Journal of Pharmaceutics, 645, 123411. doi: 10.1016/j.ijpharm.2023.123411
Journal - Research Article
2024
Journal - Research Article
Saha, T., Lyons, N., Yung, D. B. Y., Quiñones‑Mateu, M. E., Pletzer, D., & Das, S. C. (2024). Repurposing ebselen as an inhalable dry powder to treat respiratory tract infections. European Journal of Pharmaceutics & Biopharmaceutics, 195, 114170. doi: 10.1016/j.ejpb.2023.12.010
Awarded Doctoral Degree
Saha, T. (2024). Inhaled dry powder to treat respiratory infections (PhD). University of Otago, Dunedin, New Zealand. Retrieved from http://hdl.handle.net/10523/16645
2023
Journal - Research Article
Saha, T., Sinha, S., Harfoot, R., Quiñones‑Mateu, M. E., & Das, S. C. (2023). Inhalable dry powder containing remdesivir and disulfiram: Preparation and in vitro characterization. International Journal of Pharmaceutics, 645, 123411. doi: 10.1016/j.ijpharm.2023.123411
Saha, T., Sinha, S., Harfoot, R., Quiñones‑Mateu, M. E., & Das, S. C. (2023). Spray-dried inhalable microparticles combining remdesivir and ebselen against SARS-CoV-2 infection. Pharmaceutics, 15, 2229. doi: 10.3390/pharmaceutics15092229
Conference Contribution - Published proceedings: Full paper
Saha, T., Sinha, S., Harfoot, R., Quiñones‑Mateu, M. E., & Das, S. C. (2023). Development of inhalable dry powders combining replication and protease inhibitors of SARS-CoV-2. Proceedings of the 34th Drug Delivery to the Lungs (DDL) Conference. 34, (pp. 389-392). Retrieved from https://ddl-conference.com
Conference Contribution - Published proceedings: Abstract
Saha, T., Lyons, N., Yung, D., Pletzer, D., Quiñones Mateu, M. E., & Das, S. (2023). Inhalable ebselen dry powder for respiratory tract infections. Pharmacy Education, 23(6), (pp. 147). doi: 10.46542/pe.2023.236.129157
2022
Journal - Research Article
Saha, T., Quiñones‑Mateu, M. E., & Das, S. C. (2022). Inhaled therapy for COVID-19: Considerations of drugs, formulations and devices. International Journal of Pharmaceutics, 624, 122042. doi: 10.1016/j.ijpharm.2022.122042
Saha, T., Sinha, S., Harfoot, R., Quiñones Mateu, M. E., & Das, S. C. (2022). Manipulation of spray-drying conditions to develop an inhalable ivermectin dry powder. Pharmaceutics, 14(7), 1432. doi: 10.3390/pharmaceutics14071432
Conference Contribution - Published proceedings: Abstract
Saha, T., Sinha, S., Harfoot, R., Quiñones‑Mateu, M. E., & Das, S. C. (2022). Development of remdesivir and ebselen containing inhalable dry powder for COVID-19. Proceedings of the Australasian Pharmaceutical Science Association (APSA) and the Australasian Society of Clinical and Experimental Pharmacologists and Toxicologists (ASCEPT) Joint Conference. 566. Retrieved from https://www.asceptasm.com
Conference Contribution - Poster Presentation (not in published proceedings)
Saha, T., Sinha, S., Harfoot, R., Quiñones‑Mateu, M. E., & Das, S. C. (2022, November). Inhalable dry powder of synergistic drug combinations to treat COVID-19. Poster session presented at the Otago Global Health Institute (OGHI) 14th Annual Conference: Reimagining Partnerships, Dunedin, New Zealand.
Conference Contribution - Verbal presentation and other Conference outputs
Saha, T., Sinha, S., Harfoot, R., Quiñones‑Mateu, M. E., & Das, S. C. (2022, November). Inhalable dry powder containing remdesivir and disulfiram for COVID-19. Verbal presentation at the School of Pharmacy Research Day, Dunedin, New Zealand.
Saha, T., Sinha, S., Harfoot, R., Quiñones‑Mateu, M. E., & Das, S. C. (2022, November). Remdesivir and ebselen containing inhalable dry powder against SARS-CoV-2. Verbal presentation at the New Zealand Controlled Release Society (NZCRS) Symposium, Auckland, New Zealand.
Saha, T., Sinha, S., Harfoot, R., Quiñones‑Mateu, M. E., & Das, S. C. (2022, November). Inhalable antivirals for SARS-CoV-2 infections. Verbal presentation at the Bioengineering@Otago Showcase, [Online].
2021
Journal - Research Other
Saha, T., Khadka, P., & Das, S. C. (2021). Alcohol-based hand sanitizer: Composition, proper use and precautions. Germs, 11(3), 408-417. doi: 10.18683/germs.2021.1278
2020
Conference Contribution - Published proceedings: Abstract
Das, S. C., Saha, T., Shah, R., Wood, N., Adhikari, B., Bastola, R., Khadka, P., & Marra, C. A. (2020). Hand sanitizer for hand hygiene during COVID-19 in New Zealand: A response to the community's need by staff and students of the School of Pharmacy, University of Otago. Proceedings of the Australasian Society of Clinical and Experimental Pharmacologists and Toxicologists (ASCEPT) and the Australasian Pharmaceutical Science Association (APSA) Joint Scientific Meeting: Global Solutions for Global Challenges. Retrieved from https://www.asceptasm.com/2020-annual-scientific-meeting